| Followers | 11 |
| Posts | 1459 |
| Boards Moderated | 0 |
| Alias Born | 02/01/2013 |
Wednesday, May 21, 2014 12:48:30 AM
Actually, it's a pretty good bet that they will do business with Pfizer again.
The whole astrazenica thing is smoke in the wind, the real news will be another tie up with Organovo. The last deal Pfizer inked with Organovo was worth over 1/2 $million ($600,000) for the original 40 day liver assays as an R&D project.
Having that business relationship already in place makes further deals that much easier, as anyone doing business with a large corp could tell you. Once you get your foot in the door, and Pfizer gets comfortable when a deal goes through like it did. Success breeds success. And others on this board have noted they know insiders at Pfizer and there is a lot of buzz about the ONVO printed tissues.
Let's also not forget L'oreal using Organovo printed skin tissue for their next gen skin care products.
And the Michael J Fox organisation working with Parkinson's could be a huge customer for testing samples of organ tissues...
Just sayin there is sooo much upside here.
The whole astrazenica thing is smoke in the wind, the real news will be another tie up with Organovo. The last deal Pfizer inked with Organovo was worth over 1/2 $million ($600,000) for the original 40 day liver assays as an R&D project.
Having that business relationship already in place makes further deals that much easier, as anyone doing business with a large corp could tell you. Once you get your foot in the door, and Pfizer gets comfortable when a deal goes through like it did. Success breeds success. And others on this board have noted they know insiders at Pfizer and there is a lot of buzz about the ONVO printed tissues.
Let's also not forget L'oreal using Organovo printed skin tissue for their next gen skin care products.
And the Michael J Fox organisation working with Parkinson's could be a huge customer for testing samples of organ tissues...
Just sayin there is sooo much upside here.
Recent VIVS News
- VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing • GlobeNewswire Inc. • 04/28/2026 12:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/06/2026 05:27:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:05:10 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 04/02/2026 08:00:55 PM
- VivoSim Announces Pricing of up to a $4 Million Public Offering • GlobeNewswire Inc. • 04/01/2026 12:05:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/31/2026 02:17:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 09:26:52 PM
- VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs • GlobeNewswire Inc. • 03/24/2026 12:05:00 PM
- VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales • GlobeNewswire Inc. • 03/03/2026 01:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:05:26 PM
- VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego • GlobeNewswire Inc. • 02/11/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:59:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:51:43 AM
- VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China • GlobeNewswire Inc. • 01/29/2026 09:05:00 PM
- VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer • GlobeNewswire Inc. • 01/06/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 09:05:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2025 11:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 09:08:13 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/03/2025 09:07:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/03/2025 09:06:32 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/28/2025 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2025 12:45:18 AM
